A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 08 Mar 2018 Planned number of patients changed from 140 to 143.
- 07 Feb 2018 Planned End Date changed from 30 Apr 2019 to 24 Jun 2019.
- 09 Nov 2017 Status changed from suspended to recruiting.